Multicenter, Randomized, Double-Blind, Parallel Group Trial to Evaluate Efficacy and Safety of PT009 Compared to PT005 in COPD Exacerbations Over a 52-Week Treatment Period in Subjects with Moderate to Very Severe COPD
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ASTRAZENECA FARMACEUTICA ESPAÑA SA
- Phase: II
- Execution start: 22/11/2016
- End of execution: 30/08/2018
- PI: BERNARDINO ALCAZAR NAVARRETE